None
EN
Bristol-Myers $300 million IP spinout is latest example of pharma ‘externalisation’ strategy
['Adam Houldsworth', 'View Full Biography']
IAM
Register for limited accessRegister to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited accessGet news, unique commentary, expert analysis and essential resources from the IAM experts.
['latest'
'ip'
'resources'
'spinout'
'receive'
'million'
'unlimited'
'externalisation'
'limited'
'strategy'
'pharma'
'bristolmyers'
'300'
'subscriber'
'iam'
'register'
'newsletter'
'example'
'unique'
'unlock']